---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-104915"
form_type: "8-K"
ticker: "ACET"
cik: "0001720580"
company_name: "Adicet Bio, Inc."
filed_at: "2024-09-10T23:59:59+00:00"
generated_at: "2026-05-31T05:40:15.889165+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Adicet prioritizes ADI-001 for autoimmunity; closes MCL enrollment; reports 80% ORR, 60% CR

## Summary
- Focuses ADI-001 development on four autoimmune indications: lupus nephritis, SLE, systemic sclerosis, ANCA vasculitis.
- Closed Phase 1 MCL enrollment; topline results: ORR 80% (8/10), CR 60% (6/10), median CR duration 17.5 months as of Aug 22, 2024.
- Patients heavily pretreated (median 3 prior therapies); 30% had progressed on prior CAR T; no GvHD, low grade ≥3 CRS/neurotoxicity.
- Plans to present translational data from Phase 1 NHL study at CAR-TCR Summit on Sept 19, 2024 in Boston.
- Expects to expand ADI-001 clinical development into additional autoimmune indications near term.

## SEC filing metadata
- accession: 0000950170-24-104915
- form_type: 8-K
- ticker: ACET
- cik: 0001720580
- company_name: Adicet Bio, Inc.
- filed_at: 2024-09-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1720580/000095017024104915/0000950170-24-104915-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1720580/000095017024104915/acet-20240910.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-104915
- JSON: https://secwatch.observer/filing/0000950170-24-104915.json
- Plain text: https://secwatch.observer/filing/0000950170-24-104915.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.